Dr. Ruxandra Teslo reveals how China took American cancer science, engineered a better therapy, and now makes 4X the revenue: "China started to rise 10 years ago in biotech. In 2017, they had this amazing result of a Phase I trial for this therapy that was really good for this very advanced refractory blood cancer. It was called Carvitkri. That was basically the first sign that China was getting ahead." "That therapy was better than the American therapy that was quite similar. Even though the…